miR-125b Acts as a Tumor Suppressor in Breast Tumorigenesis via Its Novel Direct Targets ENPEP, CK2-α, CCNJ, and MEGF9

• Andrea Feliciano,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Josep Castellvi,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Ana Artero-Castro,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Jose A. Leal,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Cleofé Romagosa,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Javier Hernández-Losa,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Vicente Peg,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Angels Fabra,

  Affiliation Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain

  ⨯
• Francisco Vidal,

  Affiliation Banc de Sang i Teixits, Barcelona, Spain

  ⨯
• Hiroshi Kondoh,

  Affiliation Department of Geriatric Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

  ⨯
• Santiago Ramón y Cajal,

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯
• Matilde E. LLeonart

  * E-mail: melleona@ir.vhebron.net

  Affiliation Oncology and Molecular Pathology Group, Pathology Department, Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain

  ⨯